Press Releases

Investor Resources
Contact Us
Investor ResourcesPress Releases

Press Releases

Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million


January 23, 2026

Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million


January 16, 2026

Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis


January 13, 2026

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx™ Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions


December 1, 2025

Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040


November 13, 2025

Cardiol Therapeutics’ Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases


November 5, 2025

Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027


October 21, 2025

Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027


October 17, 2025

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference


August 11, 2025

2026 Cardiol Therapeutics. All right reserved.